Maze Therapeutics CSBO Sells: Reading Insider Moves
When a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
Discover why dividend ETFs incur fees, including management costs and tracking errors, and how those charges influence your long-term results.
26,393 articlesWhen a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
Circle Internet Group posted a stronger-than-expected Q1 2026, triggering a 68% year-to-date gain and a rally that ou...
The AI boom isn’t just about memory chips anymore. A broader wave of demand is lifting compute, software, and data in...
When a chief financial officer liquidates shares, investors pay attention. This article digs into maplight's just sol...
Genius Sports reported a significant top-line gain, with revenue up sharply last quarter. But a prominent investor ch...
Quantum stocks have been front and center as grants and hype push prices higher. This guide explains why infleqtion s...
A surprising signal from Nvidia's CEO has AMD investors buzzing. This article breaks down what Jensen Huang's comment...
In a choppy 2026 market, Cathie Wood isn’t chasing high-flying tech alone. She’s quietly adding to positions in three...
A major fund stepped in with a bold $30 million wager on Floor & Decor after a sharp 30% decline. This article breaks...
A 53-year-old caregiver was denied Social Security Disability Insurance after a denial tied to the recent-work test, ...
Defense technology is approaching a market shakeout as government procurement reforms accelerate purchases and ventur...
A New York-based startup unveiled an autonomous, AI-powered offensive security platform, raising $37 million from Lig...